Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Gross Profit (2016 - 2025)

Ocular Therapeutix has reported Gross Profit over the past 12 years, most recently at $11.7 million for Q4 2025.

  • Quarterly results put Gross Profit at $11.7 million for Q4 2025, down 26.47% from a year ago — trailing twelve months through Dec 2025 was $21.2 million (down 33.28% YoY), and the annual figure for FY2025 was $45.4 million, down 21.89%.
  • Gross Profit for Q4 2025 was $11.7 million at Ocular Therapeutix, up from $1.5 million in the prior quarter.
  • Over the last five years, Gross Profit for OCUL hit a ceiling of $38.9 million in Q4 2022 and a floor of -$21.9 million in Q4 2023.
  • Median Gross Profit over the past 5 years was $4.7 million (2024), compared with a mean of $7.7 million.
  • Biggest five-year swings in Gross Profit: soared 670.32% in 2023 and later tumbled 175.15% in 2025.
  • Ocular Therapeutix's Gross Profit stood at $34.0 million in 2021, then increased by 14.63% to $38.9 million in 2022, then plummeted by 156.14% to -$21.9 million in 2023, then surged by 172.54% to $15.9 million in 2024, then dropped by 26.47% to $11.7 million in 2025.
  • The last three reported values for Gross Profit were $11.7 million (Q4 2025), $1.5 million (Q3 2025), and $11.5 million (Q2 2025) per Business Quant data.